Motixafortide + G-CSF was safe and well tolerated
deaths
EVENTS
Treatment-emergent AEs (TEAEs) were defined as starting with the first dose of G-CSF through 30 days following the last apheresis procedure or the first dose of conditioning chemotherapy, whichever occurred first. Overall, TEAEs were reported in 93.8% (grade 3, 27.5%) of patients with motixafortide + G-CSF versus 83.3% (grade 3, 4.8%) with placebo + G-CSF (Table GENESIS trial safety and toxicityAll TEAEs occurring at a frequency of >10% in either motixafortide + G-CSF or placebo + G-CSF during the period from the first dose of G-CSF through 30 days following the last apheresis procedure or the first dose of conditioning chemotherapy, whichever occurred first. No grade 4 TEAEs or deaths events occurred during this period.